Remove Big Data Remove Clinical Research Remove Development Remove Trials
article thumbnail

Recognizing the Real People Behind the Big Data and Artificial Intelligence in Clinical Research

ACRP blog

If you hadn’t already noticed, the clinical research enterprise has well and truly entered the era of “big data,” artificial intelligence (AI), and machine learning. In other words, it’s about delivering ‘the right treatment to the right patient at the right time.’”

article thumbnail

ACRP Journal Article Focuses on Clinical Research in Transgender and Gender Diverse Populations

ACRP blog

Just in time to help recognize Pride Month , ACRP’s Clinical Researcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI, big data and deep real-world evidence – the challenges and opportunities

pharmaphorum

Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes. The webinar will also cover: The challenges of RWE research and how they are being overcome.

Big Data 110
article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei Heptares are looking to expedite GPCR research within not only immunology, but also gastroenterology and immuno-oncology as well, and the latest data bodes well for future development of therapeutic options in these areas.

article thumbnail

AI, big data and deep real-world evidence – the challenges and opportunities

pharmaphorum

Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes.

article thumbnail

June 26, 2023: NIMHD Director Discusses Ways Researchers Can Help Reduce Health Disparities

Rethinking Clinical Trials

Pérez-Stable, MD This year’s annual Steering Committee meeting for the NIH Pragmatic Trials Collaboratory featured health equity as a central topic of discussion. He recommended sitting down with people as equals to co-develop research. In an interview after his keynote presentation, Eliseo J.

Research 130